Hone Bio Overview

  • Year Founded
  • 2017

Year Founded

  • Status
  • Private

  • Employees
  • 6

Employees

  • Latest Deal Type
  • Accelerator/​Inc

  • Investors
  • 20

Hone Bio General Information

Description

Developer of cell membrane augmentation technology designed to treat solid tumors. The company's technology enhances cell therapies for cancer, heart disease, osteoarthritis and diabetic wound healing, enabling researchers to add new functionalities to therapies, including tissue-specific targeting and enhanced cell survivability.

Contact Information

Website
www.hone.bio
Formerly Known As
CytoSeek
Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Corporate Office
  • Science Creates Old Market
  • Midland Road
  • Bristol BS2 0JZ
  • England, United Kingdom
+44 0117
Primary Industry
Drug Discovery
Other Industries
Biotechnology
Corporate Office
  • Science Creates Old Market
  • Midland Road
  • Bristol BS2 0JZ
  • England, United Kingdom
+44 0117

Hone Bio Timeline

2023202420252026
Financing RoundCaptured Employee CountEstimated Employee Growth

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Hone Bio Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
11. Accelerator/Incubator 01-Jun-2025 Completed Generating Revenue
10. Later Stage VC 06-Sep-2023 Completed Generating Revenue
9. Early Stage VC 15-Mar-2021 Completed Generating Revenue
8. Grant 01-Jan-2020 Completed Generating Revenue
7. Seed Round 25-Nov-2019 Completed Generating Revenue
6. Angel (individual) Completed Pre-Clinical Trials
5. Grant 01-Feb-2018 Completed Pre-Clinical Trials
4. Grant 01-Jan-2018 Completed Pre-Clinical Trials
3. Grant 16-May-2017 $2.58K Completed Pre-Clinical Trials
2. Accelerator/Incubator Completed Pre-Clinical Trials
To view Hone Bio’s complete valuation and funding history, request access »

Hone Bio Cap Table

Stock # of Shares
Authorized
Par Value Dividend Rate (%) Original
Issue Price
Liquidation Liquidation
Pref. Multiple
Conversion Price % Owned
B Ordinary
B Ordinary
Ordinary
Ordinary 490 $0.126725 $121.81 $121.81 1x $121.81 0.98%
Ordinary 5,827 $0.126725 $152.17 $152.17 1x $152.17 11.64%
To view Hone Bio’s complete cap table history, request access »

VC Exit Predictor

See how our proprietary methodology utilizes historical data sets to synthesize the likelihood of an acquisition, IPO, or no exit event. Get a detailed look at the calculations behind our predictions.

Opportunity Score

Calculated using Exit Type probabilities, the company’s stage, and PitchBook’s historical returns data.

Exit Type

Evaluates the likelihood of a successful exit for investors, and the most likely exit type.

Hone Bio Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last
Financing
Details
Developer of cell membrane augmentation technology designed to treat solid tumors. The company's technology enhances cel
Drug Discovery
Bristol, United Kingdom
6 As of 2026

London, United Kingdom
 

Cambridge, United Kingdom
 
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

Hone Bio Competitors (2)

One of Hone Bio’s 2 competitors is Autolus, a Formerly VC-backed company based in London, United Kingdom.

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Autolus Formerly VC-backed London, United Kingdom
Biosceptre Venture Capital-Backed Cambridge, United Kingdom
You’re viewing 2 of 2 competitors. Get the full list »

Hone Bio Patents

Hone Bio Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
WO-2026052839-A1 Targeting fusion proteins Pending 06-Sep-2024
WO-2023144089-A1 Carboxymethl dextran used as crosslinker in immunotherapy Inactive 25-Jan-2022
GB-202200962-D0 Polymer additives Inactive 25-Jan-2022
AU-2020231078-A1 Antitumor cell comprising a charge modified globin Inactive 06-Mar-2019
CA-3131161-A1 Antitumor cell comprising a charge modified globin Pending 06-Mar-2019 A61K35/17
To view Hone Bio’s complete patent history, request access »

Hone Bio Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Hone Bio Investors (20)

Investor Name Investor Type Holding Investor Since Participating Rounds
Science Creates Accelerator/Incubator
KCP Nominees Corporation Minority
Luminous Ventures (Healthcare) Venture Capital Minority
Meltwind Advisory Venture Capital Minority
Outsized Ventures Venture Capital Minority
You’re viewing 5 of 20 investors. Get the full list »

Hone Bio FAQs

  • When was Hone Bio founded?

    Hone Bio was founded in 2017.

  • Where is Hone Bio headquartered?

    Hone Bio is headquartered in Bristol, United Kingdom.

  • What is the size of Hone Bio?

    Hone Bio has 6 total employees.

  • What industry is Hone Bio in?

    Hone Bio’s primary industry is Drug Discovery.

  • Is Hone Bio a private or public company?

    Hone Bio is a Private company.

  • What is Hone Bio’s current revenue?

    The current revenue for Hone Bio is .

  • How much funding has Hone Bio raised over time?

    Hone Bio has raised $7.33M.

  • Who are Hone Bio’s investors?

    Science Creates, KCP Nominees, Luminous Ventures (Healthcare), Meltwind Advisory, and Outsized Ventures are 5 of 20 investors who have invested in Hone Bio.

  • Who are Hone Bio’s competitors?

    Autolus and Biosceptre are competitors of Hone Bio.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process